ADVERTISEMENT
Adjuvant Chemotherapy Followed by Radiation May Benefit Patients With High-Risk Endometrial Cancer
According to a phase 2 trial, adjuvant chemotherapy with docetaxel and cisplatin followed by pelvic radiation therapy may benefit patients with high-risk endometrial cancer.
This open-label, single-arm trial enrolled 62 patients with endometrial cancer who had undergone staging surgery. Patients included had stage I disease with ≥2 risk factors, stage IB and II disease with clear cell or serous adenocarcinoma, stage II disease with post-type 1 hysterectomy, and stage III disease. All patients received 70 mg/m2 docetaxel plus 60 mg/m2 cisplatin for 3 cycles, followed by 45 to 50.4 Gy of pelvic radiation therapy.
Median follow-up duration was 65 months. The 1-year, 3-year, and 5-year progression-free survival rates were 98.4%, 86.9%, and 79.1%, respectively. The 1-year, 3-year, and 5-year overall survival rates were 98.4%, 96.4%, and 96.4%, respectively. After chemotherapy, there were 62.9% of patients with severe neutropenia and 3.2% had grade 3/4 anemia. The most common mild adverse events were nausea and alopecia. After radiation, there were 16.7% of patients with grade 3 neutropenia and 3.3% had grade 1/2 anemia. There were not critical toxicities reported.
According to study authors, “Patients with endometrial cancer with high-risk factors could benefit from adjuvant chemotherapy using docetaxel/cisplatin, followed by radiation therapy, with manageable toxicity.”
Source:
Kang O-J, Cho Y-J, Cheol Lim M, et al. Docetaxel/cisplatin chemotherapy followed by pelvic radiation therapy in patients with high-risk endometrial cancer after staging surgery: A phase II study. Int J Radiat Oncol Biol Phys. Published Online: November 15, 2024. doi: 10.1016/j.ijrobp.2024.11.071
